Botti Gerardo, Scognamiglio Giosuè, Cantile Monica
Pathology Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", via Mariano Semmola, 80131 Napoli, Italy.
Int J Mol Sci. 2016 Jun 30;17(7):1046. doi: 10.3390/ijms17071046.
PD-1/PD-L1 (programmed death 1/programmed death ligand 1) pathway plays a critical role in immune escape of tumor cells. Recent studies have described that PD-L1 is heterogeneously expressed in various types of cancer, although its prognostic/predictive value is still uncertain. These problems are partly due to a not well defined operating protocol for its detection by immunohistochemistry, but also because most of the studies conducted on large case series were made by Tissue Micro Array (TMA). We are going to discuss this latter point, to highlight that TMA must be set up in an appropriate manner, especially for some markers, such as PD-L1, which, besides being poorly expressed in tumor cells, can be expressed by cells of the tumor microenvironment.
程序性死亡蛋白1/程序性死亡配体1(PD-1/PD-L1)通路在肿瘤细胞的免疫逃逸中起着关键作用。最近的研究表明,PD-L1在各种类型的癌症中呈异质性表达,尽管其预后/预测价值仍不确定。这些问题部分归因于免疫组织化学检测其操作流程尚未明确界定,也因为大多数针对大病例系列开展的研究是通过组织微阵列(TMA)进行的。我们将讨论后一点,以强调必须以适当方式构建TMA,特别是对于某些标志物,如PD-L1,其不仅在肿瘤细胞中表达不佳,还可由肿瘤微环境中的细胞表达。